Pharmaceutical Care for Asthma Control Improvement (PHARMACI)-Study - Full Text View

Sponsored by:	University Ghent
Information provided by:	University Ghent
ClinicalTrials.gov Identifier:	NCT00263159

Purpose

The objective of this study is to evaluate the therapeutic effectiveness and cost-effectivity of pharmaceutical care for asthma patients.

Condition	Intervention
Asthma	Procedure: Pharmaceutical care for asthma patients

MedlinePlus related topics: Asthma

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Randomized, Open Label, Placebo Control, Parallel Assignment, Efficacy Study
Official Title:	Pharmaceutical Care for Asthma Control Improvement

Further study details as provided by University Ghent:

Primary Outcome Measures:

The difference between study groups in the change of asthma control from baseline and follow-up visits [ Time Frame: after 1, 3 and 6 months ]

Secondary Outcome Measures:

Peak flow [ Time Frame: after 3 and 6 months ]
Knowledge of asthma and treatment [ Time Frame: after 6 months ]
Asthma quality of life questionnaire (AQLQ) [ Time Frame: after 6 months ]
Therapy adherence
Inhalation techniques [ Time Frame: after 6 months ]
Smoking [ Time Frame: after 6 months ]
Asthma exacerbations [ Time Frame: after 6 months ]
General Practitioner (GP) visits, emergency room visits and hospitalisations
Working days lost and school days lost

Enrollment:	221
Study Start Date:	January 2006
Study Completion Date:	October 2006

Detailed Description:

The objective of this study is to evaluate the therapeutic effectiveness and cost-effectivity of pharmaceutical care for asthma patients. Patients will be randomly allocated to the control group (= no input from pharmacist) or intervention group (= with pharmaceutical care at baseline and follow-up visits over 6 months).

Eligibility

Ages Eligible for Study:	18 Years to 50 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients with persistent asthma
Asthma treatment for at least 12 months
Regular visitors of the participating community pharmacy

Exclusion Criteria:

Severe co-morbidity
> 10 pack-years smoking history
Asthma Control Test score < 15 or =25

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00263159

Locations

Belgium
University Hospital Ghent
Ghent, Belgium, 9000

Sponsors and Collaborators

University Ghent

Investigators

Principal Investigator:

Guy Brusselle, MD, PhD

University Hospital, Ghent

More Information

Website of the University Ghent This link exits the ClinicalTrials.gov site

Study ID Numbers:	2005/320
Study First Received:	December 6, 2005
Last Updated:	December 19, 2007
ClinicalTrials.gov Identifier:	NCT00263159
Health Authority:	Belgium: Institutional Review Board

Study placed in the following topic categories:

Hypersensitivity
Lung Diseases, Obstructive
Respiratory Tract Diseases
Lung Diseases

Hypersensitivity, Immediate
Asthma
Respiratory Hypersensitivity

Additional relevant MeSH terms:

Immune System Diseases
Bronchial Diseases

ClinicalTrials.gov processed this record on January 16, 2009